<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05056909</url>
  </required_header>
  <id_info>
    <org_study_id>Kidney ACTion</org_study_id>
    <nct_id>NCT05056909</nct_id>
  </id_info>
  <brief_title>Kidney AI-enabled Care Transformation</brief_title>
  <official_title>Kidney AI-enabled Care Transformation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fraunhofer Institut für Arbeitswirtschaft und Organisation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Empirica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IN-JET APS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CNET Svenska AB</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>XIGME</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European ESKD Patients' Federation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Manchester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Università degli studi di Verona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Diagnostics International AG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federación Nacional ALCER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the Kidney ACTion study, CKD (Chronic Kidney Disease) patients at increased risk of&#xD;
      progression to ESRD (End Stage Renal Disease) will be randomly assigned to either standard of&#xD;
      care in a specialist nephrology outpatient clinic or to receiving CKD care supported by a&#xD;
      novel AI-supported (Artificial Intelligence) software solution.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Advancing American Kidney Health (AAKH) initiative has the goal of an ambitious 25%&#xD;
      reduction of ESRD incidence by 2030. There is a lack of successful integrated care programs&#xD;
      to reach this goal. The CKD population is very heterogeneous, this explains the different&#xD;
      risk of progression to ESRD in different patients. However, Guidelines (GLs) for the&#xD;
      treatment of CKD patients address risk factors identified in the CKD population at large.&#xD;
      Thus, all CKD patients at the same stage receive similar treatments no matter the specific&#xD;
      risk of developing ESRD. Up to 5.9% of Europeans have CKD stages 3-5. Treating this huge&#xD;
      number of patients would strain health systems from both the organizational and economical&#xD;
      point of view. It is reasonable to think that dedicating a personalized management&#xD;
      specifically to CKD patients at high risk of progression would be cost-effective.&#xD;
&#xD;
      GLs include behavioral (e.g. lifestyle, nutrition) as well as medical (e.g. drug therapy)&#xD;
      interventions. Although patient's engagement and empowerment play a pivotal role in&#xD;
      successful disease treatment, there is lack of evidence on practices to foster them in CKD&#xD;
      patients.&#xD;
&#xD;
      Kidney ACTion is a program that supports nephrologists in predicting disease progression for&#xD;
      CKD patients and developing multidisciplinary, personalized, evidence-based treatment and&#xD;
      care plans. Patient engagement and empowerment is a fundamental part of the program.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2022</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Albumin to Creatinine Ratio (UACR)</measure>
    <time_frame>1 year after start of treatment</time_frame>
    <description>Urine Albumin (mg/dL) / Urine Creatinine (g/dL) = UACR in mg/g ≈ Albumin excretion in mg/day</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CKD care, as routinely provided in the respective nephrology outpatient clinic.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>standard of care + Kidney ACTion AI-supported software for chronic kidney disease care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Kidney ACTion</intervention_name>
    <description>AI-supported software for chronic kidney disease care</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged ≥18 years at the time of signing the informed consent&#xD;
&#xD;
          -  Chronic kidney disease with eGFR &lt;45 mL/min/1.73 m2 and UACR &gt;300 mg/g creatinine&#xD;
             (eGFR=estimated glomerular filtration rate; UACR=Urine Albumin-to-Creatinine Ratio)&#xD;
&#xD;
          -  Patient is willing to comply with the study requirements for therapy during the entire&#xD;
             study period&#xD;
&#xD;
          -  Patient is capable of providing written informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with underlying renal disease likely to receive disease-specific therapy&#xD;
             other than SoC (Standard of Care)&#xD;
&#xD;
          -  Patient expected to require renal replacement therapy within less than one year from&#xD;
             study inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander H Kirsch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander H Kirsch, MD</last_name>
    <phone>+43316385</phone>
    <phone_ext>12170</phone_ext>
    <email>alexander.kirsch@medunigraz.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathrin Eller, MD</last_name>
    <phone>+43316385</phone>
    <phone_ext>12170</phone_ext>
    <email>kathrin.eller@medunigraz.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Università Cattolica del Sacre Cuore</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Giovanni Gambaro, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Leicester</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Ruper Major, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>September 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic kidney disease</keyword>
  <keyword>End stage kidney disease</keyword>
  <keyword>Artificial intelligence</keyword>
  <keyword>Patient engagement</keyword>
  <keyword>Progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

